What is moleculin biotech's (mbrx) stock price today?
Moleculin Biotech, Inc.'s stock symbol is MBRX and currently trades under NASDAQ. It’s current price per share is approximately $ 2.98. What are your Moleculin Biotech, Inc. (MBRX) stock predictions?
What does mbrx stand for?
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin, we or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended September 30, 2021.
Where can I buy mbrx shares?
Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is MBRX stock a good buy?
The consensus among 3 Wall Street analysts covering (NASDAQ: MBRX) stock is to Strong Buy MBRX stock.
Will MBRX stock go up?
Moleculin Biotech Inc (NASDAQ:MBRX) The 3 analysts offering 12-month price forecasts for Moleculin Biotech Inc have a median target of 14.00, with a high estimate of 29.00 and a low estimate of 5.00. The median estimate represents a +872.22% increase from the last price of 1.44.
What is the long range forecast for Mbrx stock?
On average, Wall Street analysts predict that Forte Biosciences's share price could reach $3.25 by Sep 20, 2022. The average Forte Biosciences stock price prediction forecasts a potential upside of 155.91% from the current FBRX share price of $1.27.
How has Moleculin Biotech's stock price performed in 2022?
Moleculin Biotech's stock was trading at $1.86 at the start of the year. Since then, MBRX stock has decreased by 19.4% and is now trading at $1.50....
Are investors shorting Moleculin Biotech?
Moleculin Biotech saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 248,500 shares, an increa...
When is Moleculin Biotech's next earnings date?
Moleculin Biotech is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for M...
How were Moleculin Biotech's earnings last quarter?
Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its earnings results on Wednesday, May, 11th. The company reported ($0.24) EPS for the quarter, missin...
When did Moleculin Biotech's stock split? How did Moleculin Biotech's stock split work?
Moleculin Biotech shares reverse split on Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number o...
Who are Moleculin Biotech's key executives?
Moleculin Biotech's management team includes the following people: Mr. Walter V. Klemp , Founder, Chairman, Pres & CEO (Age 62, Pay $891.66k) Mr...
Who are some of Moleculin Biotech's key competitors?
Some companies that are related to Moleculin Biotech include ProPhase Labs (PRPH) , LumiraDx (LMDX) , Concert Pharmaceuticals (CNCE) , Oramed P...
What other stocks do shareholders of Moleculin Biotech own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuti...
What is Moleculin Biotech's stock symbol?
Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."
About Moleculin Biotech
Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses.
Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development
Moleculin Biotech's stock was trading at $3.0306 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MBRX stock has decreased by 53.5% and is now trading at $1.41. View which stocks have been most impacted by COVID-19.
WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech
HOUSTON, Feb. 14, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti...
Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference
VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that it has entered into an amended and r...
Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myel..
HOUSTON, Jan. 20, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...
Moleculin to Present at the H.C. Wainwright BioConnect Conference
HOUSTON, Jan. 18, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin...
Read Why Is Roth Capital Bullish On This Cancer-Focused Stock
HOUSTON, Jan. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...
Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme
Roth Capital notes that the FDA cleared Moleculin Biotech Inc's (NASDAQ:MBRX) WP1122 to start a Phase 1 trial in glioblastoma multiforme, which will be in addition to the drug's impending parallel clini...
Read Why Is Roth Capital Bullish On This Cancer-Focused Stock
HOUSTON, Dec. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting high...
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Roth Capital notes that the FDA cleared Moleculin Biotech Inc's (NASDAQ: MBRX) WP1122 to start a Phase 1 trial in glioblastoma multiforme, which will be in addition to the drug's impending parallel clinical development in COVID-19.
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18)
Signals & Forecast
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development.
Is Moleculin Biotech Inc stock A Buy?
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Insiders are very positive buying more shares than they are selling in Moleculin Biotech Inc
Moleculin Biotech Inc holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
In the last 60 trades there were 6.34 million shares bought and 333.24 thousand shares sold. The last trade was done 226 days ago by Klemp Walter V who bough 13.21 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
